475 related articles for article (PubMed ID: 31957470)
1. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Byrne NJ; Matsumura N; Maayah ZH; Ferdaoussi M; Takahara S; Darwesh AM; Levasseur JL; Jahng JWS; Vos D; Parajuli N; El-Kadi AOS; Braam B; Young ME; Verma S; Light PE; Sweeney G; Seubert JM; Dyck JRB
Circ Heart Fail; 2020 Jan; 13(1):e006277. PubMed ID: 31957470
[TBL] [Abstract][Full Text] [Related]
2. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
Gordon M; Meagher P; Connelly KA
Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
[TBL] [Abstract][Full Text] [Related]
3. Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure.
Byrne NJ; Soni S; Takahara S; Ferdaoussi M; Al Batran R; Darwesh AM; Levasseur JL; Beker D; Vos DY; Schmidt MA; Alam AS; Maayah ZH; Schertzer JD; Seubert JM; Ussher JR; Dyck JRB
Circ Heart Fail; 2020 Jun; 13(6):e006573. PubMed ID: 32493060
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
5. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
6. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
7. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies.
Liu P; Zhang Z; Wang J; Zhang X; Yu X; Li Y
Bioengineered; 2021 Dec; 12(2):9356-9366. PubMed ID: 34823419
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin directly improves diastolic function in human heart failure.
Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Hundertmark MJ; Adler A; Antoniades C; Coleman R; Griffin JL; Holman RR; Lamlum H; Lee J; Massey D; Miller JJJJ; Milton JE; Monga S; Mózes FE; Nazeer A; Raman B; Rider O; Rodgers CT; Valkovič L; Wicks E; Mahmod M; Neubauer S
Circulation; 2023 May; 147(22):1654-1669. PubMed ID: 37070436
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.
Li XX; Chen ZD; Sun XJ; Yang YQ; Jin H; Liu NF
Acta Pharmacol Sin; 2024 Apr; 45(4):751-764. PubMed ID: 38172306
[TBL] [Abstract][Full Text] [Related]
16. Dapansutrile Ameliorates Atrial Inflammation and Vulnerability to Atrial Fibrillation in HFpEF Rats.
Yang H; Zhu J; Fu H; Shuai W
Heart Lung Circ; 2024 Jan; 33(1):65-77. PubMed ID: 38040503
[TBL] [Abstract][Full Text] [Related]
17. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction.
Cheng X; Zhao H; Wen X; Li G; Guo S; Zhang D
Life Sci; 2023 Nov; 333():122185. PubMed ID: 37858713
[TBL] [Abstract][Full Text] [Related]
18. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
Bayes-Genis A; Iborra-Egea O; Spitaleri G; Domingo M; Revuelta-López E; Codina P; Cediel G; Santiago-Vacas E; Cserkóová A; Pascual-Figal D; Núñez J; Lupón J
Sci Rep; 2021 Jun; 11(1):12025. PubMed ID: 34103605
[TBL] [Abstract][Full Text] [Related]
19. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca
Suetomi T; Willeford A; Brand CS; Cho Y; Ross RS; Miyamoto S; Brown JH
Circulation; 2018 Nov; 138(22):2530-2544. PubMed ID: 30571348
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
